This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
While the immune system can eliminate cancer, it can also contribute to cancer growth under certain conditions. HMGB1 is an important immune molecule that plays a role in this process and may have immense value in the clinic. Dr. Bassi wants to understand more about its activity, so he’s analyzing tumor-immune interactions in a mouse cancer model and determining how differential HMGB1 activity influences breast cancer progression as well as responses to immunotherapy and chemotherapy. In this way, he hopes to reveal insights about new targets that guide new approaches to improve patient outcomes.
University Health Network (Canada) | Breast Cancer | 2016 | Tak W. Mak, Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
New research, new treatments, and how we’re working toward a future immune to cervical cancer
Ugur Sahin and Ozlem Tureci, two of this year’s CRI Coley Award recipients, are pioneers of the mRNA vaccines helping us confront COVID-19 and cancer.